Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01500512 | Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection(GROINSS-V) | unknown | — | 148 | Gynecologic Oncology GroupNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT03942380 | Cell-free Tumor DNA in Head and Neck Cancer Patients | unknown | N/A | 500 | Christian von BuchwaldOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03800953 | The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03387904 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04109573 | Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)(FLAN) | unknown | N/A | 20 | Homerton University Hospital NHS Foundation TrustOTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT05024019 | Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | unknown | Phase 2 | 95 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT05024266 | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma(TACT) | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04514835 | A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC | unknown | Phase 2 | 44 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04063683 | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC). | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05013268 | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma(TiTanec) | unknown | Phase 1 | 15 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04533490 | A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT04888403 | Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04992988 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | unknown | Phase 2 | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04815629 | Outcome of Radiation Therapy in Urinary Bladder Squampus Cell Carcinoma | unknown | — | 40 | Assiut UniversityOTHER | 0 | Aug 18, 2021 | clinicaltrials |
| NCT05008796 | PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT | unknown | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT05010330 | Identify Prognostic Biomarkers of Lung Cancer | unknown | — | 500 | RenJi HospitalOTHER | 1 | Aug 18, 2021 | clinicaltrials |
| NCT04846452 | Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | unknown | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04999800 | Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 | unknown | Phase 2 | 20 | Shi YuankaiUNKNOWN | 1 | Aug 11, 2021 | clinicaltrials |
| NCT03450967 | Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC | unknown | Phase 2 | 31 | Samsung Medical CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04984018 | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 73 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04620785 | Photodynamic Therapy in Treatment of Verrucae | unknown | N/A | 80 | Alexandria UniversityOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04880811 | Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification | unknown | Phase 2 | 43 | Peking UniversityOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03766178 | Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04275986 | Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma | unknown | Phase 2 | 56 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03713749 | Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial | unknown | N/A | 212 | Chang Gung Memorial HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04851132 | Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma | unknown | N/A | 33 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04905030 | Education, Immigration and HPV Vaccination: an Informational Randomized Trial | unknown | N/A | 2,500 | Karolinska InstitutetOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04922450 | Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT04270201 | Determination of ALDH1b1 and ALDH2 Polymorphisms Frequency in the Brazilian Population(ALDH2020) | unknown | — | 300 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04628806 | Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells(HSP70CTC) | unknown | — | 120 | Charite University, Berlin, GermanyOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04882462 | Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.(Carpp-1) | unknown | Phase 2 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | May 12, 2021 | clinicaltrials |
| NCT03134846 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate(ICON) | unknown | Phase 1 / Phase 2 | 79 | University Medical Center GroningenOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT04866381 | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody | unknown | Phase 2 | 87 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 155 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT04523883 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)(IMPORT) | unknown | Phase 2 | 316 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02661152 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.(DAHANCA30) | unknown | Phase 3 | 1,252 | Danish Head and Neck Cancer GroupNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04196985 | 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC(HENEPET) | unknown | N/A | 40 | Turku University HospitalOTHER_GOV | 1 | Apr 13, 2021 | clinicaltrials |
| NCT03585530 | Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 32 | Huai'an First People's HospitalOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04832555 | Non Elective Vulnerable Elderly Radiotherapy(NEVER) | unknown | N/A | 100 | Azienda Ospedaliero Universitaria Policlinico ModenaOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | unknown | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04813406 | Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | unknown | N/A | 53 | Henan Provincial People's HospitalOTHER | 0 | Mar 24, 2021 | clinicaltrials |
| NCT03791905 | PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 216 | Mian XIOTHER | 1 | Mar 23, 2021 | clinicaltrials |
| NCT03771820 | Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen | unknown | Phase 2 | 136 | NanoCarrier Co., Ltd.INDUSTRY | 8 | Mar 17, 2021 | clinicaltrials |
| NCT04797507 | SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer | unknown | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 0 | Mar 15, 2021 | clinicaltrials |
| NCT02054442 | A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck(COMMENCE) | unknown | Phase 1 / Phase 2 | 52 | Radboud University Medical CenterOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT04780750 | Concurent Chemoradiotherapy in Head and Neck Cancers | unknown | Phase 3 | 60 | Assiut UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04766827 | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor | unknown | Phase 4 | 116 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2021source: clinicaltrials